Abstract: SA-PO455
Impact of Multimorbidity on Patient-Reported Quality of Life – Analysis of a Real World CKD Patient Population
Session Information
- CKD: Cognitive Dysfunction, Depression, Quality of Life
November 04, 2017 | Location: Hall H, Morial Convention Center
Abstract Time: 10:00 AM - 10:00 AM
Category: Chronic Kidney Disease (Non-Dialysis)
- 306 CKD: Cognitive Dysfunction, Depression, Quality of Life
Authors
- Jackson, James, Adelphi Group, Macclesfield, United Kingdom
- Hadfield, Anna, Adelphi Real World, Macclesfield, United Kingdom
- Moon, Rebecca, Adelphi Group, Macclesfield, United Kingdom
Background
It is widely accepted that the prevalence of anemia, secondary hyperparathyroidism (SHPT) and hyperkalemia amongst chronic kidney disease (CKD) patients increases as CKD worsens. The objective of this analysis was to determine whether an increase in the number of CKD related comorbidities has an impact on patient quality of life (QoL).
Methods
Data were drawn from the Adelphi CKD Disease Specific Programme (DSP), a real-world, cross-sectional survey of consulting non-dialysis (ND) and dialysis CKD patients across 5EU and USA. Patients were segmented according to the number of physician-reported, CKD-related comorbidities (anemia, SHPT and/or hyperkalemia) experienced and patient-reported QoL was assessed using EuroQol-5D-3L (EQ-5D).
Results
Results from 1758 CKD patients showed that as CKD worsened, patients were more likely to experience multiple comorbid conditions (Figure 1). An increase in multimorbidity at Stage 3-ND and Stage 4-ND was associated with a decrease in patient-reported QoL. For Stage 4-ND patients, a significant reduction was observed in the mean EQ-5D score for patients with 3 conditions compared with those who have 0 conditions (Figure 1). Although a similar trend was not observed amongst the Dialysis population, the QoL scores were lower overall than those patients at an earlier stage (Figure 1).
Conclusion
Multimorbidity increases as CKD progresses. Increased multimorbidity is associated with a poorer quality of life for CKD patients. Slowing disease progression could help prevent the onset of anemia, SHPT and/or hyperkalemia leading to maintenance of better QoL for longer.